Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
62.4(c) 62.36(c) 62.75(c) 64.7(c) 65.37 Last
454 917 326 964 308 403 508 928 592 781 Volume
-3.90% -0.06% +0.63% +3.11% +1.04% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 174 M - -
Net income 2021 -68,2 M - -
Net cash position 2021 296 M - -
P/E ratio 2021 -109x
Yield 2021 -
Sales 2022 241 M - -
Net income 2022 -14,5 M - -
Net cash position 2022 377 M - -
P/E ratio 2022 -194x
Yield 2022 -
Capitalization 6 815 M 6 815 M -
EV / Sales 2021 37,5x
EV / Sales 2022 26,7x
Nbr of Employees 232
Free-Float 96,5%
More Financials
Company
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic... 
Sector
Biotechnology & Medical Research
Calendar
09/29 | 09:20amPresentation
More about the company
Ratings of Arrowhead Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ARROWHEAD PHARMACEUTICALS, INC.
09/14INSIDER SELL : Arrowhead Pharmaceuticals
MT
09/10INSIDER SELL : Arrowhead Pharmaceuticals
MT
09/01ARROWHEAD PHARMACEUTICALS : to Participate in Upcoming September 2021 Conferences
BU
08/27ARROWHEAD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/27James Hassard, the Former Chief Commercial Officer of Arrowhead Pharmaceuticals, Inc. I..
CI
08/10ARROWHEAD PHARMACEUTICALS : HC Wainwright Adjusts Arrowhead Pharmaceuticals' Price Target ..
MT
08/06ARROWHEAD PHARMACEUTICALS : Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $..
MT
08/05ARROWHEAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
08/05Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended Ju..
CI
08/05ARROWHEAD PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial..
AQ
08/05ARROWHEAD PHARMACEUTICALS : Reports Fiscal 2021 Third Quarter Results
BU
08/05EARNINGS REACTION HISTORY : Arrowhead Pharma Inc, 62.5% Follow-Through Indicator, 8.3% Sen..
MT
07/29ARROWHEAD PHARMACEUTICALS : Receives Breakthrough Therapy Designation from U.S. FDA for AR..
BU
07/29Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation by the U.S. Food an..
CI
07/29Arrowhead Gets FDA Breakthrough Therapy Designation for ARO-AAT
DJ
More news
News in other languages on ARROWHEAD PHARMACEUTICALS, INC.
09/14VENTE D'INITIÉS : Arrowhead Pharmaceuticals
09/10VENTE D'INITIÉS : Arrowhead Pharmaceuticals
2018WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2018Arrowhead conclut un accord avec J&J, son titre bondit
More news
Analyst Recommendations on ARROWHEAD PHARMACEUTICALS, INC.
More recommendations
Chart ARROWHEAD PHARMACEUTICALS, INC.
Duration : Period :
Arrowhead Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARROWHEAD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 64,70 $
Average target price 87,92 $
Spread / Average Target 35,9%
EPS Revisions
Managers and Directors
Christopher Richard Anzalone President, Chief Executive Officer & Director
Kenneth Allen Myszkowski Chief Financial Officer
Douglass B. Given Chairman
Javier San Martin Chief Medical Officer
Jeff Ketelhut Vice President-Information Technology & Systems
Sector and Competitors
1st jan.Capi. (M$)
ARROWHEAD PHARMACEUTICALS, INC.-14.81%6 746
GILEAD SCIENCES, INC.22.19%89 886
BIONTECH SE309.08%85 255
WUXI APPTEC CO., LTD.34.39%68 592
REGENERON PHARMACEUTICALS32.25%67 216
VERTEX PHARMACEUTICALS-22.31%48 018